Small Molecule Tyrosine Kinase Inhibitor Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global small molecule tyrosine kinase inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Small molecule tyrosine kinase inhibitors (TKIs) block intracellular signalling pathways in tumor cells which leads to deregulation of key cell functions that include proliferation and differentiation. Additionally, as per the National Center for Biotechnology Information (NCBI), Small molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy. The major factor for the growth of the market is the increasing prevalence of cancer across the globe.
To Request a Sample of our Report on Small Molecule
Tyrosine Kinase Inhibitor Market: https://www.omrglobal.com/request-sample/small-molecule-tyrosine-kinase-inhibitor-market
According to the National Cancer
Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be
diagnosed in the US with a mortality rate of 606,520 people in 2020.
Furthermore, there were 18.1 million new cases and 9.5 million cancer-related
mortalities globally in 2018 which is anticipated to rise to 29.5 million and
the number of cancer-related mortalities to 16.4 million by 2040. Hence, the
rising prevalence of cancer is increasing the demand for small molecule
tyrosine kinase inhibitors which in turn is driving the growth of the global
small molecule tyrosine kinase inhibitor market.
Some major players in the market include Merck KGaA,
Novartis International AG, and Pfizer Inc., among others. The market players
are contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical expansion,
partnerships and collaborations, and new product launches, to stay competitive
in the market. For instance, in September 2020, Seattle Genetics has granted
Merck an exclusive license to commercialize TUKYSA (tucatinib), a small
molecule tyrosine kinase inhibitor in Asia, the Middle East and Latin America
and other regions outside of the US, Canada and Europe. TUKYSA is used for the
treatment of HER2-positive cancers
Market Coverage
• The market number available for –
2020-2027
• Base year- 2020
• Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
Merck KGaA, Novartis International AG, and Pfizer Inc., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Small Molecule Tyrosine Kinase Inhibitor Market is Available @ https://www.omrglobal.com/industry-reports/small-molecule-tyrosine-kinase-inhibitor-market
Global Small Molecule Tyrosine Kinase Inhibitor Market
Report by Segment
By Type
• Phase-I
• Phase-I/II
• Phase-II
• Phase-II/III
• Phase-III
By Application
• Lung Cancer
• Breast Cancer
• Others
Global Small Molecule Tyrosine Kinase Inhibitor Market
Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment